Tremfya’s skin clearance benefit lasts up to four years in plaque psoriasis patients, Janssen says

pharmafile | June 15, 2020 | News story | Research and Development, Sales and Marketing Janssen, Tremfya, plaque psoriasis 

Janssen has revealed new data on its interleukin (IL)-23 inhibitor Tremfya (guselkumab) at the American Academy of Dermatology (AAD) virtual event this year, showing that use of the drug led to high levels of skin clearance up to four years after commencing treatment in plaque psoriasis patients.

Phase 3 data demonstrated that, in patients who received 100mg Tremfya every eight weeks, 80% of this population saw an improvement of at least 90% improvement in their Psoriasis Area and Severity Index (PASI 90) score four years later.

Over the same period, 82% of this group achieved either skin clearance or minimal disease (a score of 0 or 1, respectively) on the Investigator’s Global Assessment (IGA) scale, with 51% achieving complete clearance.

It was also reported that 69% of all participants saw no impact of their disease on their quality of life after four years, as measured by a score of 0 or 1 on the Dermatology Life Quality Index, while 40% were symptom-free and 27% were sign-free over the same period, according to scores on the Psoriasis Symptoms and Signs Diary metric.

Earlier in treatment, patients were evaluated at 48 weeks and it was found that 42% of Tremfya patients were symptom-free compared to 23% treated with AbbVie’s blockbuster Humira (adalimumab), and 36% were found to be sign-free compared to 19%, respectively.

“Psoriasis patients are often burdened by physical pain and discomfort, and providing long-term relief from the disease is also important in alleviating the related impact to patients’ quality of life,” said Dr Kristian Reich, lead investigator on the study and Professor of Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf. “Results from the VOYAGE 2 study demonstrate guselkumab as an efficacious therapy through four years, providing patients who may be experiencing chronic psoriatic symptoms with a long-term treatment option.”

Matt Fellows

Related Content


Janssen submits sNDA to FDA for full approval of Balversa

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental …

FDA approved Janssen’s Akeega for prostate cancer treatment

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and …


FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and …

Latest content